GBT Guerbet SA

GUERBET : Financial agenda for 2026

GUERBET : Financial agenda for 2026

Financial agenda for 2026

Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2026.

Publications calendar
  • 2025 ANNUAL REVENUE
February 05, 2026, after trading
  • 2025 ANNUAL RESULTS
March 11, 2026, after trading
  • 2026 1ST QUARTER REVENUE
April 23, 2026, after trading
  • ANNUAL SHAREHOLDERS’ MEETING
May 22, 2026
  • 2026 2ND QUARTER REVENUE
July 23, 2026, after trading
  • 2026 FIRST HALF RESULTS
September 15, 2026, after trading
  • 2026 3RD QUARTER REVENUE
October 22, 2026, after trading

About Guerbet

At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 98 years, with more than 2,905 employees worldwide, we continuously innovate and devote 9% of our revenue to Research and Development in four centers in France and the United States. Guerbet (GBT) is listed in compartment B of Euronext Paris and generated revenue of €841m in 2024. For more information, please visit .



Contacts:

Guerbet     

Christine Allard, SVP Public Affairs and Corporate Communications 82 /

Seitosei.Actifin                                                                                       

Marianne Py, Financial Communication 93 /

Anne-Claire Taton, Press 18 /

Attachment



EN
19/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Guerbet SA

 PRESS RELEASE

GUERBET : Financial agenda for 2026

GUERBET : Financial agenda for 2026 Financial agenda for 2026 Villepinte, November 19, 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2026. Publications calendar 2025 ANNUAL REVENUE February 05, 2026, after trading 2025 ANNUAL RESULTS March 11, 2026, after trading 2026 1ST QUARTER REVENUE April 23, 2026, after trading ANNUAL SHAREHOLDERS’ MEETING May 22, 2026 2026 2ND QUARTER REVENUE July 23, 2026, after trading 2026 FIRST HALF RESULTS September 15, 2026, after tradi...

 PRESS RELEASE

GUERBET : Calendrier financier de l’exercice 2026

GUERBET : Calendrier financier de l’exercice 2026 Calendrier financier de l’exercice 2026 Villepinte, le 19 novembre 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son calendrier financier pour l’exercice 2026. Dates des publications CHIFFRE D’AFFAIRES ANNUEL 2025 5 février 2026, après bourse RÉSULTATS ANNUELS 2025 11 mars 2026, après bourse CHIFFRE D’AFFAIRES DU 1ER TRIMESTRE 2026 23 avril 2026, après bourse ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES 22 mai 2026 CHIFFRE D’AFFAIRES DU 2ÈME TRIMESTRE 2026 ...

Guerbet Sa: 1 director

A director at Guerbet Sa bought 1,190 shares at 15.000EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch